-2%
Fylox is indicated for the management of:
- Bronchial asthma
- Bronchospasm
- Chronic obstructive pulmonary disease (COPD)
- Pulmonary conditions associated with bronchial spasm
Doxophylline is a modern bronchodilator structurally distinct from theophylline due to the presence of a dioxolane group at position 7. It works primarily by selectively inhibiting phosphodiesterase-4 (PDE-4), resulting in relaxation of bronchial smooth muscles.
Unlike theophylline, it has minimal affinity for adenosine A1 and A2 receptors, which contributes to its improved safety profile. Additionally, it inhibits platelet-activating factor (PAF) and reduces leukotriene synthesis, further supporting its bronchodilatory effects.
Overdose may cause severe arrhythmias and seizures.
- Discontinue treatment immediately
- Provide symptomatic and supportive care
- No specific antidote is available
Always follow the physician’s prescription.